The antimicrobial potential of bacteriophages

This is a House of Commons Committee report, with recommendations to government. The Government has two months to respond.

The further development of phage therapies face significant challenges that will need to be overcome if their potential is to be fully realised. Like many personalised medicines, they currently struggle to meet regulations designed for conventional medicines produced to a single formulation. In the UK phages have not been manufactured to required Good Manufacturing Process (GMP) standards, precluding UK-produced phages from clinical use. The small quantities of phages that have been used in the UK are imported, usually not to GMP standards, and are heavily restricted because they are unlicensed.